The most established predictive factor so far is the degree of PSMA expression in the tumor, with higher tumor uptake (quantified by whole body tumor SUVmean) associated with better response to treatment, suggesting the potential for further optimization of patient selection (4–6). This evidence concerns the gene FOLH1 and neoplasm.